平安健康(检测)中心与GE医疗签署战略合作协议,共筑医疗共享经济新业态

2020-11-08 平安健康(检测)中心 平安健康(检测)中心

11月6日,在第三届中国国际进口博览会上,平安医疗健康管理股份有限公司(简称“平安医保科技”)旗下平安健康(检测)中心与通用电气公司旗下的GE医疗业务集团(简称“G

11月6日,在第三届中国国际进口博览会上,平安医疗健康管理股份有限公司(简称“平安医保科技”)旗下平安健康(检测)中心与通用电气公司旗下的GE医疗业务集团(简称“GE”医疗)签署战略合作。根据协议,双方将基于各自领域的优势,为中国客户提供开创医疗护理新时代的革新性医疗器械产品、技术解决方案和服务,共同促进“健康中国2030”战略目标的实现。


平安健康(检测)中心作为中国平安打造“医疗生态圈”战略中的重要一环,在全国首创集影像诊断、医学检验、健康管理“三位一体”的创新业态,以打造医疗领域的共享经济,推进分级诊疗,促进健康服务业发展,实现区域医疗资源共享为导向,致力于为广大客户提供更便捷、更精准、更安全的创新型健康检测服务。
图说:平安健康(检测)中心与GE医疗签约
 
近年来,国家连续出台政策大力推动健康产业发展。2018年6月19日,国卫医发【2018】19号文显示,公立医疗机构可以委托独立设置的医学影像诊断中心、医学检验实验室和病理诊断中心等提供的第三方专业服务委托协议作为本机构相关诊疗科目的登记依据。大趋势下,第三方医疗是国家推动分级诊疗、鼓励社会办医的重要方向。
本次,双方签约将在现有各项业务合作的基础上,充分发挥平安健康(检测)中心专业的第三方服务医疗经验以及GE医疗的资源优势,在设备市场化、学科建设、教育培训、运营科技赋能、品牌宣传及行业发声、科研合作等领域展开合作。

例如,在学科建设方面,双方将充分发挥自身优势,就心脏、乳腺、肿瘤等专病的影像临床应用进行深入探讨和交流,打造基于专病的影像综合解决方案。同时,GE医疗将充分利用自身医疗机构、专家资源优势,进一步推动平安健康(检测)中心与医院形成合作,打造心脏、乳腺、肿瘤等专病的“早筛-诊断-治疗-康复”闭环管理模式。在教育培训方面,GE医疗将携手平安健康(检测)中心共同建立包括但不限于战略运营、变革创新、管理艺术、效能提升、职业发展等方面完善的专业人才培训体系,并打造赋能行业的管理学院。

医学检测的技术水平和诊断水平是保障医学质量的关键所在,目前,第三方独立影像中心面临的最大问题是人才的制约,急需同公立医院一样建立合理的人才梯队。目前,平安健康(检测)中心不仅是拥有科研级的影像设备,更聚集了权威专家资源。此次,GE医疗也将为平安健康(检测)中心的专业技术人员提供配套的系统化应用培训,提供三甲医院进修培养、专家讲座及学术论坛参会等机会,将自身的影像教育培训资源嫁接至平安健康(检测)中心的影像教育平台,有望共同打造业内领先的影像教育学院,通过建立医学影像行业金标准,提供高水平和标准化的影像诊断服务,从而推动整个行业的快速发展。

GE医疗CEO张轶昊表示:“人才的培养也是一个长期的过程,而这需要多方共同努力,在提升医师水准上,我们将一如既往的组织医师培训。我们也希望此次携手平安健康(检测)中心,通过为专业技术人员提供专项技能培训,提高个人和各大科室的综合业务水平,共同为国家输送高端科研技术人才,改善基层服务能力,提高基层卫生服务的可及性,推动医疗资源的横向整合、纵向流动、优质资源均衡布局,实现‘强基层、促健康、降成本’的改革目标。”

第三方医疗是国家推动分级诊疗、鼓励社会办医的重要方向。第三方医疗行业通过与多方合作必然会充分有效地赋能公立医疗机构,推动国家分级诊疗的实现,为百姓提供高品质医疗健康服务。平安健康(检测)中心也将继续携手多方,以专业精准的高质量医疗检测与诊断服务,促进健康产业发展,为实现“健康中国2030”宏伟目标贡献一份力量。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1769245, encodeId=ed151e6924578, content=<a href='/topic/show?id=aad14885340' target=_blank style='color:#2F92EE;'>#平安健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48853, encryptionId=aad14885340, topicName=平安健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea0e37999606, createdName=xinmeili, createdTime=Mon Dec 21 23:14:33 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394720, encodeId=0b221394e20d8, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Nov 11 04:14:33 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478270, encodeId=d3f714e8270ab, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Wed Nov 11 04:14:33 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591358, encodeId=7517159135855, content=<a href='/topic/show?id=436d299e33d' target=_blank style='color:#2F92EE;'>#共享#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29973, encryptionId=436d299e33d, topicName=共享)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 11 04:14:33 CST 2020, time=2020-11-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1769245, encodeId=ed151e6924578, content=<a href='/topic/show?id=aad14885340' target=_blank style='color:#2F92EE;'>#平安健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48853, encryptionId=aad14885340, topicName=平安健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea0e37999606, createdName=xinmeili, createdTime=Mon Dec 21 23:14:33 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394720, encodeId=0b221394e20d8, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Nov 11 04:14:33 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478270, encodeId=d3f714e8270ab, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Wed Nov 11 04:14:33 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591358, encodeId=7517159135855, content=<a href='/topic/show?id=436d299e33d' target=_blank style='color:#2F92EE;'>#共享#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29973, encryptionId=436d299e33d, topicName=共享)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 11 04:14:33 CST 2020, time=2020-11-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1769245, encodeId=ed151e6924578, content=<a href='/topic/show?id=aad14885340' target=_blank style='color:#2F92EE;'>#平安健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48853, encryptionId=aad14885340, topicName=平安健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea0e37999606, createdName=xinmeili, createdTime=Mon Dec 21 23:14:33 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394720, encodeId=0b221394e20d8, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Nov 11 04:14:33 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478270, encodeId=d3f714e8270ab, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Wed Nov 11 04:14:33 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591358, encodeId=7517159135855, content=<a href='/topic/show?id=436d299e33d' target=_blank style='color:#2F92EE;'>#共享#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29973, encryptionId=436d299e33d, topicName=共享)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 11 04:14:33 CST 2020, time=2020-11-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1769245, encodeId=ed151e6924578, content=<a href='/topic/show?id=aad14885340' target=_blank style='color:#2F92EE;'>#平安健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48853, encryptionId=aad14885340, topicName=平安健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea0e37999606, createdName=xinmeili, createdTime=Mon Dec 21 23:14:33 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394720, encodeId=0b221394e20d8, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Nov 11 04:14:33 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478270, encodeId=d3f714e8270ab, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Wed Nov 11 04:14:33 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591358, encodeId=7517159135855, content=<a href='/topic/show?id=436d299e33d' target=_blank style='color:#2F92EE;'>#共享#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29973, encryptionId=436d299e33d, topicName=共享)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 11 04:14:33 CST 2020, time=2020-11-11, status=1, ipAttribution=)]
    2020-11-11 zhaojie88